^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    fludarabine IV

    i
    Other names: NSC 312887, NSC-312887, NSC312887
    Company:
    Generic mfg.
    Drug class:
    DNA synthesis inhibitor
    Related drugs:
    23h
    CC-95266-MM-001: A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma (clinicaltrials.gov)
    P1, N=130, Completed, Juno Therapeutics, a Subsidiary of Celgene | Active, not recruiting --> Completed
    Trial completion
    |
    cyclophosphamide • bendamustine • fludarabine IV • arlocabtagene autoleucel (BMS-986393)
    1d
    CD45RA-depleted CD19-CAR T Cell Consolidation After TCR??+ T Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma (clinicaltrials.gov)
    P1, N=60, Not yet recruiting, St. Jude Children's Research Hospital | Initiation date: Dec 2025 --> May 2026
    Trial initiation date
    |
    cyclophosphamide • melphalan • fludarabine IV • thiotepa • Neupogen (filgrastim)
    1d
    ACIT001/EXC002: Anti-CD19, Dual Co-stimulatory (4-1BB, CD3ζ) Chimeric Antigen Receptor T-cells in Patients With Relapsed/Refractory Aggressive Lymphoma or Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov)
    P1/2, N=63, Recruiting, University of Alberta | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial primary completion date
    |
    cyclophosphamide • fludarabine IV
    1d
    Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial (clinicaltrials.gov)
    P3, N=186, Recruiting, First Affiliated Hospital of Zhejiang University
    New P3 trial
    |
    Venclexta (venetoclax) • melphalan • fludarabine IV
    4d
    A Study of LCAR-G08 in Subjects With Advanced Gastrointestinal Tumors Expressing Guanylyl Cyclase C (GCC) (clinicaltrials.gov)
    P1, N=17, Terminated, Peking University | N=42 --> 17 | Trial completion date: Mar 2028 --> Oct 2025 | Recruiting --> Terminated; achieved the proof of concept
    Enrollment change • Trial completion date • Trial termination
    |
    cyclophosphamide • fludarabine IV
    4d
    An Exploratory Clinical Study on the Safety and Efficacy of Anti-CD19/BCMA U CAR-T Cells in the Treatment of Relapsed/Refractory Immune-mediated Kidney Disease (clinicaltrials.gov)
    P1, N=36, Recruiting, Changhai Hospital | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    5d
    OPTIMIZE: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis (clinicaltrials.gov)
    P2, N=313, Active, not recruiting, Center for International Blood and Marrow Transplant Research | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    cyclophosphamide • melphalan • fludarabine IV • busulfan
    5d
    Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1/2, N=66, Recruiting, National Cancer Institute (NCI) | N=132 --> 66
    Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    Rituxan (rituximab) • cyclophosphamide • fludarabine IV
    5d
    B7-H3.CD28Z.CART in CNS Neoplasms (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Robbie Majzner
    New P1 trial
    |
    CD276 (CD276 Molecule)
    |
    cyclophosphamide • fludarabine IV
    7d
    BHCT-RD06-04-05: Clinical Study on Targeted CD19CAR-T Therapy for Autoimmune Diseases (clinicaltrials.gov)
    P1, N=12, Suspended, Nanjing Bioheng Biotech Co., Ltd. | Recruiting --> Suspended
    Trial suspension
    |
    cyclophosphamide • fludarabine IV
    7d
    Allogeneic HSCT for consolidation in pediatric refractory or relapsed ALK-positive anaplastic large cell lymphoma. (PubMed, Blood Adv)
    Conditioning was based on total body irradiation (TBI) in 30 patients and on chemotherapy in 27 patients, mainly with reduced-toxicity conditioning (RTC; Treosulfan, Fludarabine, and Thiotepa). Our data support the use of TBI-free conditioning and suggest improved outcomes with unrelated donors receiving ATLG prophylaxis. NCT00317408.
    Journal
    |
    ALK (Anaplastic lymphoma kinase)
    |
    ALK positive
    |
    fludarabine IV • thiotepa • Grafapex (treosulfan)
    7d
    Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances (clinicaltrials.gov)
    P1/2, N=30, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting | N=80 --> 30
    Enrollment closed • Enrollment change
    |
    cyclophosphamide • fludarabine IV • CAR.70/IL15-transduced CB-NK cells